INVEST SECURITIES - Innate Pharma : Les rendez-vous sont pris - ACHAT, OC : 9,4€
Vendredi dernier, nous avons eu l'occasion d'organiser le RS à Paris d'INNATE Pharma avec le management de la société. De ce rendez-vous post journée R&D, nous retenons principalement 3 points: (i) un portefeuille diversifié et complémentaire en immunothérapie avec trois actifs first-in-class en clinique, (ii) de potentielles nouvelles collaborations sur IPH 5401 et (iii) un newsflow clinique dense concernant monalizumab (résultats possibles lors de l'AACR et/ou l'ASCO?) et IPH 4102 au S2 18. Avec une sous valorisation manifeste et l'entrée possible de deux produits en phase pivot l'année prochaine, nous maintenons notre opinion à ACHAT avec un OC inchangé de 9,4€.Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.